FDA Approves DOXYCYCLINE — Lupin Pharmaceuticals, Inc.

Lupin Pharmaceuticals, Inc. secured FDA approval on March 5, 2014, for its generic Doxycycline oral tablets, positioning the company to capture market share in the commodity antibiotic sector. This approval expands Lupin's generic portfolio and is expected to drive revenue growth while increasing competitive pricing for the widely used drug.